^
BIOMARKER:

RAS wild-type

i
Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
RAS wild-type
CRC
anlotinib
Sensitive: C3 – Early Trials
BMC Med - 2 weeks - (New C3)
RAS wild-type
CRC
regorafenib
Sensitive: A1 - Approval
RAS wild-type
CRC
panitumumab
Sensitive: A1 - Approval
RAS wild-type
CRC
fruquintinib
Sensitive: B - Late Trials
RAS wild-type
CRC
bevacizumab
Sensitive: B - Late Trials
RAS wild-type
CRC
ramucirumab
Sensitive: C2 – Inclusion Criteria
RAS wild-type
CRC
cetuximab
Sensitive: C2 – Inclusion Criteria
RAS wild-type
CRC
bevacizumab + cetuximab
Sensitive: C2 – Inclusion Criteria
RAS wild-type
CRC
EGFR inhibitor
Sensitive: C3 – Early Trials
RAS wild-type
CRC
avelumab
Sensitive: C3 – Early Trials
RAS wild-type
Colon Cancer
cetuximab
Resistant: C3 – Early Trials